Akili Inc

Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its leveraging technologies designed to directly target the brain establishes a new category of medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. The company is headquartered in Boston, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Akili Inc reports strong Q4 performance, focuses on ADHD market

Akili Inc's Q4 2022 earnings call highlighted strong performance in operational efficiency and clinical trial outcomes.
The company's focus on driving adoption of EndeavorRx and engaging older kids in treatment presents growth opportunities.
Challenges include uncertainties in extrapolating findings to adult studies and investigating treatment engagement across subgroups.
Overall, Akili Inc's strategic initiatives position it well for future growth in the ADHD marketplace.

Akili Inc reports robust Q1 performance, poised for ADHD market expansion

Akili Inc's Q1 2023 showcased strong performance and promising results in the mental health treatment space. With a focus on driving adoption and expanding coverage for Endeavor Rx, Akili aims to solidify its position in the ADHD market. The company's well-funded status and unique technology provide a strong foundation for future growth.

Akili Inc reports flat Q2 revenue, eyes FDA OTC designation

Akili Inc faced revenue challenges in Q2 2023 due to insurance issues but maintained a strong cash position supporting operations until Q1 2025.
The launch of EndeavorOTC for adults with ADHD and its potential FDA OTC designation present growth opportunities for Akili.
Despite challenges, Akili's diversified product portfolio, including EndeavorRx, positions the company well for future market expansion and revenue growth.

Akili Inc reports 500% revenue growth in Q3 2023

Akili Inc's Q3 2023 earnings call showcased strong financial performance, strategic shifts towards a nonprescription model, and a focus on improving unit economics. The company's reaffirmed financial guidance, collaborations, and regulatory progress indicate a positive outlook. Challenges around customer acquisition and market competition were also highlighted.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its technologies are designed to directly target the physiology of the brain. The company was founded by W. Edward Martucci II and Adam Gazzaley in December 2020 and is headquartered in Boston, MA.

Akili, Inc. (NASDAQ:AKLI ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Joshua Young - IR Walter Martucci - Co-Founder, CEO & Director Matthew Franklin - President & COO Santosh Shanbhag - CFO & Treasurer Conference Call Participants Charles Rhyee - Cowen Judah Frommer - Crédit Suisse Rahul Rakhit - LifeSci Capital Operator Greetings, and welcome to Akili's Third Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode.

Akili, Inc. (AKLI) Q3 2022 Earnings Call Transcript

BOSTON--( BUSINESS WIRE )--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended September 30, 2022, and provided an update on business progress.

Akili Reports Third Quarter 2022 Financial Results and Company Update

Akili is developing video games as a means to treat ADHD, depression, and other conditions. The company has approval by the FDA to treat ADHD using its product EndeavorRx. It is also approved to market in "the European Economic Area."

Akili: Developing Video Games To Treat Cognitive Impairments

BOSTON--(BUSINESS WIRE)--Akili, Inc. (NASDAQ: AKLI), a leading digital medicine company, today announced the appointment of Mary Hentges to the company's board of directors, effective October 25, 2022.

Financial Industry Veteran Mary Hentges Joins Akili's Board of Directors

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its third quarter financial results on Thursday, November 10, 2022 at 4:30 p.m.

Akili to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 10 at 4:30 p.m. ET

BOSTON--(BUSINESS WIRE)---- $AKLI--Akili Interactive (“Akili”), a leading digital medicine company, today announced the EndeavorRx® Expedition product registry, which aims to obtain feedback from patients receiving the digital therapeutic, and their caregivers, to determine the real-world effectiveness of EndeavorRx. EndeavorRx is the first and only prescription video game treatment cleared by the U.S. Food and Drug Administration (FDA) and is indicated to improve attention function in 8-12 year old chil

Akili Launches EndeavorRx® Expedition - A Direct-to-Patient Product Registry

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that management will present at a fireside chat and participate in a panel discussion on prescription digital therapeutics at the virtual LifeSci Partners HealthTech Symposium on Tuesday, September 20, 2022. Details are as follows: Format: Presentation and Fireside Chat Time: 9:30 a.m. ET Format: Panel Discussion Topic: Prescription Digital Therapeutics Time: 11:30 a.m. ET Live and archived

Akili to Participate in LifeSci Partners HealthTech Symposium

News for Akili Inc Stock (AKLI)